Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce

(Length of Discussion: 8 min)

Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency.  Alan presents the molecular selection criteria, the design of the trial and the initial look at the first 85 patients in this study of heavily pretreated patients.

Biographies:

Alan H. Bryce, MD, Medical Director of the Genomic Oncology Clinic at Mayo Clinic, Arizona

Charles J. Ryan, MD
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe